nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxorubicin—ABCG2—Riluzole—amyotrophic lateral sclerosis	0.365	1	CbGbCtD
Doxorubicin—Congestive cardiomyopathy—Riluzole—amyotrophic lateral sclerosis	0.0128	0.041	CcSEcCtD
Doxorubicin—Skin candida—Riluzole—amyotrophic lateral sclerosis	0.0116	0.0373	CcSEcCtD
Doxorubicin—ABCB8—tongue—amyotrophic lateral sclerosis	0.00773	0.0604	CbGeAlD
Doxorubicin—NOS3—hindlimb—amyotrophic lateral sclerosis	0.00557	0.0436	CbGeAlD
Doxorubicin—Proctitis—Riluzole—amyotrophic lateral sclerosis	0.0055	0.0176	CcSEcCtD
Doxorubicin—Epirubicin—PLA2G4A—amyotrophic lateral sclerosis	0.00491	1	CrCbGaD
Doxorubicin—Skin nodule—Riluzole—amyotrophic lateral sclerosis	0.00484	0.0155	CcSEcCtD
Doxorubicin—NOS3—appendage—amyotrophic lateral sclerosis	0.00478	0.0374	CbGeAlD
Doxorubicin—Faecalith—Riluzole—amyotrophic lateral sclerosis	0.0047	0.015	CcSEcCtD
Doxorubicin—Faecaloma—Riluzole—amyotrophic lateral sclerosis	0.0047	0.015	CcSEcCtD
Doxorubicin—NOS1—nerve—amyotrophic lateral sclerosis	0.00446	0.0348	CbGeAlD
Doxorubicin—Skin mass—Riluzole—amyotrophic lateral sclerosis	0.00433	0.0139	CcSEcCtD
Doxorubicin—Hemiplegia—Riluzole—amyotrophic lateral sclerosis	0.00376	0.012	CcSEcCtD
Doxorubicin—Rectal tenesmus—Riluzole—amyotrophic lateral sclerosis	0.0036	0.0115	CcSEcCtD
Doxorubicin—CBR3—embryo—amyotrophic lateral sclerosis	0.00357	0.0279	CbGeAlD
Doxorubicin—Hypochromic anaemia—Riluzole—amyotrophic lateral sclerosis	0.00346	0.0111	CcSEcCtD
Doxorubicin—NOS1—hindbrain—amyotrophic lateral sclerosis	0.00334	0.0261	CbGeAlD
Doxorubicin—NDUFS3—hindbrain—amyotrophic lateral sclerosis	0.00328	0.0256	CbGeAlD
Doxorubicin—Fungal skin infection—Riluzole—amyotrophic lateral sclerosis	0.00321	0.0103	CcSEcCtD
Doxorubicin—Furunculosis—Riluzole—amyotrophic lateral sclerosis	0.00316	0.0101	CcSEcCtD
Doxorubicin—Pericarditis—Riluzole—amyotrophic lateral sclerosis	0.0031	0.00994	CcSEcCtD
Doxorubicin—Proctalgia—Riluzole—amyotrophic lateral sclerosis	0.00286	0.00917	CcSEcCtD
Doxorubicin—Peripheral vascular disorder—Riluzole—amyotrophic lateral sclerosis	0.00274	0.00877	CcSEcCtD
Doxorubicin—Furuncle—Riluzole—amyotrophic lateral sclerosis	0.00274	0.00877	CcSEcCtD
Doxorubicin—Pneumothorax—Riluzole—amyotrophic lateral sclerosis	0.0027	0.00864	CcSEcCtD
Doxorubicin—Muscle relaxant therapy—Riluzole—amyotrophic lateral sclerosis	0.0027	0.00864	CcSEcCtD
Doxorubicin—Vaginal moniliasis—Riluzole—amyotrophic lateral sclerosis	0.00266	0.00852	CcSEcCtD
Doxorubicin—Bundle branch block—Riluzole—amyotrophic lateral sclerosis	0.00266	0.00852	CcSEcCtD
Doxorubicin—Lymphopenia—Riluzole—amyotrophic lateral sclerosis	0.00262	0.0084	CcSEcCtD
Doxorubicin—Vulvovaginal candidiasis—Riluzole—amyotrophic lateral sclerosis	0.00255	0.00818	CcSEcCtD
Doxorubicin—Hypotonia—Riluzole—amyotrophic lateral sclerosis	0.00255	0.00818	CcSEcCtD
Doxorubicin—Vulvovaginal mycotic infection—Riluzole—amyotrophic lateral sclerosis	0.00246	0.00786	CcSEcCtD
Doxorubicin—Anorectal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00246	0.00786	CcSEcCtD
Doxorubicin—Urine abnormality—Riluzole—amyotrophic lateral sclerosis	0.00242	0.00776	CcSEcCtD
Doxorubicin—Body temperature decreased—Riluzole—amyotrophic lateral sclerosis	0.00239	0.00767	CcSEcCtD
Doxorubicin—Hypothermia—Riluzole—amyotrophic lateral sclerosis	0.00239	0.00767	CcSEcCtD
Doxorubicin—Gingival bleeding—Riluzole—amyotrophic lateral sclerosis	0.00237	0.00758	CcSEcCtD
Doxorubicin—Gastric ulcer—Riluzole—amyotrophic lateral sclerosis	0.00231	0.0074	CcSEcCtD
Doxorubicin—Urine analysis abnormal—Riluzole—amyotrophic lateral sclerosis	0.00228	0.00731	CcSEcCtD
Doxorubicin—Generalised oedema—Riluzole—amyotrophic lateral sclerosis	0.00226	0.00723	CcSEcCtD
Doxorubicin—Enlargement abdomen—Riluzole—amyotrophic lateral sclerosis	0.00223	0.00715	CcSEcCtD
Doxorubicin—Polyp—Riluzole—amyotrophic lateral sclerosis	0.00221	0.00707	CcSEcCtD
Doxorubicin—Myasthenia—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00684	CcSEcCtD
Doxorubicin—Psoriasis—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00684	CcSEcCtD
Doxorubicin—Oral candidiasis—Riluzole—amyotrophic lateral sclerosis	0.00211	0.00677	CcSEcCtD
Doxorubicin—Embolism—Riluzole—amyotrophic lateral sclerosis	0.00209	0.0067	CcSEcCtD
Doxorubicin—Cyst—Riluzole—amyotrophic lateral sclerosis	0.00201	0.00643	CcSEcCtD
Doxorubicin—Hypokinesia—Riluzole—amyotrophic lateral sclerosis	0.00199	0.00637	CcSEcCtD
Doxorubicin—Seborrhoeic dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00197	0.00631	CcSEcCtD
Doxorubicin—Hyperventilation—Riluzole—amyotrophic lateral sclerosis	0.00195	0.00625	CcSEcCtD
Doxorubicin—Haematemesis—Riluzole—amyotrophic lateral sclerosis	0.00193	0.00619	CcSEcCtD
Doxorubicin—Hypercalcaemia—Riluzole—amyotrophic lateral sclerosis	0.00193	0.00619	CcSEcCtD
Doxorubicin—NOS1—brainstem—amyotrophic lateral sclerosis	0.00191	0.015	CbGeAlD
Doxorubicin—Lung disorder—Riluzole—amyotrophic lateral sclerosis	0.0019	0.00607	CcSEcCtD
Doxorubicin—Ileus—Riluzole—amyotrophic lateral sclerosis	0.0019	0.00607	CcSEcCtD
Doxorubicin—Thrombosis—Riluzole—amyotrophic lateral sclerosis	0.0019	0.00607	CcSEcCtD
Doxorubicin—NDUFS3—brainstem—amyotrophic lateral sclerosis	0.00188	0.0147	CbGeAlD
Doxorubicin—Laryngitis—Riluzole—amyotrophic lateral sclerosis	0.00186	0.00596	CcSEcCtD
Doxorubicin—Haemoptysis—Riluzole—amyotrophic lateral sclerosis	0.00181	0.00581	CcSEcCtD
Doxorubicin—Neuritis—Riluzole—amyotrophic lateral sclerosis	0.0018	0.00576	CcSEcCtD
Doxorubicin—ABCB8—nervous system—amyotrophic lateral sclerosis	0.00178	0.0139	CbGeAlD
Doxorubicin—AKR1A1—medulla oblongata—amyotrophic lateral sclerosis	0.00176	0.0138	CbGeAlD
Doxorubicin—Pleural effusion—Riluzole—amyotrophic lateral sclerosis	0.00175	0.00561	CcSEcCtD
Doxorubicin—Amblyopia—Riluzole—amyotrophic lateral sclerosis	0.00174	0.00557	CcSEcCtD
Doxorubicin—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.00172	0.00552	CcSEcCtD
Doxorubicin—ABCB8—central nervous system—amyotrophic lateral sclerosis	0.00171	0.0134	CbGeAlD
Doxorubicin—CBR3—nervous system—amyotrophic lateral sclerosis	0.00171	0.0134	CbGeAlD
Doxorubicin—Abscess—Riluzole—amyotrophic lateral sclerosis	0.0017	0.00543	CcSEcCtD
Doxorubicin—ABCB8—cerebellum—amyotrophic lateral sclerosis	0.00167	0.0131	CbGeAlD
Doxorubicin—Ageusia—Riluzole—amyotrophic lateral sclerosis	0.00166	0.00531	CcSEcCtD
Doxorubicin—Glycosuria—Riluzole—amyotrophic lateral sclerosis	0.00166	0.00531	CcSEcCtD
Doxorubicin—CBR3—central nervous system—amyotrophic lateral sclerosis	0.00165	0.0129	CbGeAlD
Doxorubicin—Petechiae—Riluzole—amyotrophic lateral sclerosis	0.00163	0.00523	CcSEcCtD
Doxorubicin—CBR3—cerebellum—amyotrophic lateral sclerosis	0.00161	0.0126	CbGeAlD
Doxorubicin—Liver injury—Riluzole—amyotrophic lateral sclerosis	0.0016	0.00511	CcSEcCtD
Doxorubicin—AKR1A1—spinal cord—amyotrophic lateral sclerosis	0.00157	0.0123	CbGeAlD
Doxorubicin—Delirium—Riluzole—amyotrophic lateral sclerosis	0.00156	0.005	CcSEcCtD
Doxorubicin—Breast pain—Riluzole—amyotrophic lateral sclerosis	0.00154	0.00493	CcSEcCtD
Doxorubicin—Amenorrhoea—Riluzole—amyotrophic lateral sclerosis	0.00153	0.00489	CcSEcCtD
Doxorubicin—Ventricular extrasystoles—Riluzole—amyotrophic lateral sclerosis	0.00149	0.00476	CcSEcCtD
Doxorubicin—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.00149	0.00476	CcSEcCtD
Doxorubicin—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00473	CcSEcCtD
Doxorubicin—Arthropathy—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00473	CcSEcCtD
Doxorubicin—Thinking abnormal—Riluzole—amyotrophic lateral sclerosis	0.00147	0.0047	CcSEcCtD
Doxorubicin—Cough increased—Riluzole—amyotrophic lateral sclerosis	0.00147	0.0047	CcSEcCtD
Doxorubicin—Glossitis—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00466	CcSEcCtD
Doxorubicin—Nocturia—Riluzole—amyotrophic lateral sclerosis	0.00145	0.00463	CcSEcCtD
Doxorubicin—NDUFS7—spinal cord—amyotrophic lateral sclerosis	0.00143	0.0112	CbGeAlD
Doxorubicin—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00454	CcSEcCtD
Doxorubicin—Ulcer—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00454	CcSEcCtD
Doxorubicin—Blood bilirubin increased—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00454	CcSEcCtD
Doxorubicin—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.00138	0.0044	CcSEcCtD
Doxorubicin—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00438	CcSEcCtD
Doxorubicin—ABCB8—brain—amyotrophic lateral sclerosis	0.00136	0.0106	CbGeAlD
Doxorubicin—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.00136	0.00435	CcSEcCtD
Doxorubicin—Ventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00134	0.0043	CcSEcCtD
Doxorubicin—Hepatocellular injury—Riluzole—amyotrophic lateral sclerosis	0.00134	0.0043	CcSEcCtD
Doxorubicin—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.00134	0.0043	CcSEcCtD
Doxorubicin—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.00134	0.0043	CcSEcCtD
Doxorubicin—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.00134	0.0043	CcSEcCtD
Doxorubicin—Injection site reaction—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00427	CcSEcCtD
Doxorubicin—NOS1—medulla oblongata—amyotrophic lateral sclerosis	0.00133	0.0104	CbGeAlD
Doxorubicin—Dermatitis contact—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00425	CcSEcCtD
Doxorubicin—Abnormal dreams—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00425	CcSEcCtD
Doxorubicin—NDUFS2—medulla oblongata—amyotrophic lateral sclerosis	0.00133	0.0104	CbGeAlD
Doxorubicin—AKR1A1—nervous system—amyotrophic lateral sclerosis	0.00132	0.0103	CbGeAlD
Doxorubicin—Melaena—Riluzole—amyotrophic lateral sclerosis	0.00131	0.0042	CcSEcCtD
Doxorubicin—NDUFS3—medulla oblongata—amyotrophic lateral sclerosis	0.00131	0.0102	CbGeAlD
Doxorubicin—CBR3—brain—amyotrophic lateral sclerosis	0.00131	0.0102	CbGeAlD
Doxorubicin—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.00128	0.0041	CcSEcCtD
Doxorubicin—Fluid retention—Riluzole—amyotrophic lateral sclerosis	0.00127	0.00408	CcSEcCtD
Doxorubicin—AKR1A1—central nervous system—amyotrophic lateral sclerosis	0.00127	0.00996	CbGeAlD
Doxorubicin—Aplastic anaemia—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00404	CcSEcCtD
Doxorubicin—AKR1A1—cerebellum—amyotrophic lateral sclerosis	0.00124	0.00973	CbGeAlD
Doxorubicin—DHCR7—medulla oblongata—amyotrophic lateral sclerosis	0.00124	0.00973	CbGeAlD
Doxorubicin—Cramps of lower extremities—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00395	CcSEcCtD
Doxorubicin—Coma—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00393	CcSEcCtD
Doxorubicin—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00389	CcSEcCtD
Doxorubicin—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00389	CcSEcCtD
Doxorubicin—NDUFS7—nervous system—amyotrophic lateral sclerosis	0.0012	0.0094	CbGeAlD
Doxorubicin—Pulmonary oedema—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00383	CcSEcCtD
Doxorubicin—NOS1—spinal cord—amyotrophic lateral sclerosis	0.00119	0.0093	CbGeAlD
Doxorubicin—NDUFS2—spinal cord—amyotrophic lateral sclerosis	0.00118	0.00924	CbGeAlD
Doxorubicin—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00377	CcSEcCtD
Doxorubicin—NDUFS3—spinal cord—amyotrophic lateral sclerosis	0.00117	0.00913	CbGeAlD
Doxorubicin—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.00116	0.00373	CcSEcCtD
Doxorubicin—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00116	0.00373	CcSEcCtD
Doxorubicin—NDUFS7—central nervous system—amyotrophic lateral sclerosis	0.00116	0.00905	CbGeAlD
Doxorubicin—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.00114	0.00366	CcSEcCtD
Doxorubicin—YWHAG—medulla oblongata—amyotrophic lateral sclerosis	0.00114	0.00893	CbGeAlD
Doxorubicin—Phlebitis—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00362	CcSEcCtD
Doxorubicin—NDUFS7—cerebellum—amyotrophic lateral sclerosis	0.00113	0.00885	CbGeAlD
Doxorubicin—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00359	CcSEcCtD
Doxorubicin—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00359	CcSEcCtD
Doxorubicin—AURKA—nervous system—amyotrophic lateral sclerosis	0.00112	0.00874	CbGeAlD
Doxorubicin—Hepatic function abnormal—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00357	CcSEcCtD
Doxorubicin—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00355	CcSEcCtD
Doxorubicin—DHCR7—spinal cord—amyotrophic lateral sclerosis	0.00111	0.00868	CbGeAlD
Doxorubicin—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00349	CcSEcCtD
Doxorubicin—Eczema—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00347	CcSEcCtD
Doxorubicin—AURKA—central nervous system—amyotrophic lateral sclerosis	0.00108	0.00841	CbGeAlD
Doxorubicin—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00344	CcSEcCtD
Doxorubicin—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00332	CcSEcCtD
Doxorubicin—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00331	CcSEcCtD
Doxorubicin—RALBP1—medulla oblongata—amyotrophic lateral sclerosis	0.00103	0.00806	CbGeAlD
Doxorubicin—YWHAG—spinal cord—amyotrophic lateral sclerosis	0.00102	0.00796	CbGeAlD
Doxorubicin—Purpura—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00324	CcSEcCtD
Doxorubicin—AKR1A1—brain—amyotrophic lateral sclerosis	0.00101	0.00791	CbGeAlD
Doxorubicin—Anaphylactoid reaction—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00322	CcSEcCtD
Doxorubicin—NOS1—nervous system—amyotrophic lateral sclerosis	0.001	0.00784	CbGeAlD
Doxorubicin—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.000999	0.0032	CcSEcCtD
Doxorubicin—NDUFS2—nervous system—amyotrophic lateral sclerosis	0.000996	0.00779	CbGeAlD
Doxorubicin—NDUFS3—nervous system—amyotrophic lateral sclerosis	0.000984	0.00769	CbGeAlD
Doxorubicin—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.000978	0.00313	CcSEcCtD
Doxorubicin—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.000974	0.00312	CcSEcCtD
Doxorubicin—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.000974	0.00312	CcSEcCtD
Doxorubicin—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.000974	0.00312	CcSEcCtD
Doxorubicin—NOS1—central nervous system—amyotrophic lateral sclerosis	0.000965	0.00755	CbGeAlD
Doxorubicin—CBR1—medulla oblongata—amyotrophic lateral sclerosis	0.000962	0.00753	CbGeAlD
Doxorubicin—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.000959	0.00307	CcSEcCtD
Doxorubicin—Migraine—Riluzole—amyotrophic lateral sclerosis	0.000959	0.00307	CcSEcCtD
Doxorubicin—NDUFS2—central nervous system—amyotrophic lateral sclerosis	0.000959	0.0075	CbGeAlD
Doxorubicin—AKR1C3—medulla oblongata—amyotrophic lateral sclerosis	0.00095	0.00743	CbGeAlD
Doxorubicin—NDUFS3—central nervous system—amyotrophic lateral sclerosis	0.000947	0.00741	CbGeAlD
Doxorubicin—NOS1—cerebellum—amyotrophic lateral sclerosis	0.000943	0.00738	CbGeAlD
Doxorubicin—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.000941	0.00301	CcSEcCtD
Doxorubicin—NDUFS2—cerebellum—amyotrophic lateral sclerosis	0.000937	0.00733	CbGeAlD
Doxorubicin—DHCR7—nervous system—amyotrophic lateral sclerosis	0.000935	0.00731	CbGeAlD
Doxorubicin—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.000927	0.00297	CcSEcCtD
Doxorubicin—NDUFS3—cerebellum—amyotrophic lateral sclerosis	0.000926	0.00724	CbGeAlD
Doxorubicin—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.000923	0.00296	CcSEcCtD
Doxorubicin—RALBP1—spinal cord—amyotrophic lateral sclerosis	0.000919	0.00719	CbGeAlD
Doxorubicin—NDUFS7—brain—amyotrophic lateral sclerosis	0.000919	0.00718	CbGeAlD
Doxorubicin—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.000916	0.00293	CcSEcCtD
Doxorubicin—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.000906	0.0029	CcSEcCtD
Doxorubicin—DHCR7—central nervous system—amyotrophic lateral sclerosis	0.0009	0.00704	CbGeAlD
Doxorubicin—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.0009	0.00288	CcSEcCtD
Doxorubicin—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.00089	0.00285	CcSEcCtD
Doxorubicin—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.000887	0.00284	CcSEcCtD
Doxorubicin—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.000881	0.00282	CcSEcCtD
Doxorubicin—DHCR7—cerebellum—amyotrophic lateral sclerosis	0.00088	0.00688	CbGeAlD
Doxorubicin—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.000878	0.00281	CcSEcCtD
Doxorubicin—POR—medulla oblongata—amyotrophic lateral sclerosis	0.000868	0.00679	CbGeAlD
Doxorubicin—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.000862	0.00276	CcSEcCtD
Doxorubicin—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.000859	0.00275	CcSEcCtD
Doxorubicin—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.000859	0.00275	CcSEcCtD
Doxorubicin—CBR1—spinal cord—amyotrophic lateral sclerosis	0.000858	0.00671	CbGeAlD
Doxorubicin—YWHAG—nervous system—amyotrophic lateral sclerosis	0.000858	0.00671	CbGeAlD
Doxorubicin—AURKA—brain—amyotrophic lateral sclerosis	0.000854	0.00668	CbGeAlD
Doxorubicin—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.000848	0.00272	CcSEcCtD
Doxorubicin—AKR1C3—spinal cord—amyotrophic lateral sclerosis	0.000847	0.00663	CbGeAlD
Doxorubicin—Asthma—Riluzole—amyotrophic lateral sclerosis	0.000842	0.0027	CcSEcCtD
Doxorubicin—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.000842	0.0027	CcSEcCtD
Doxorubicin—Influenza—Riluzole—amyotrophic lateral sclerosis	0.000842	0.0027	CcSEcCtD
Doxorubicin—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.000826	0.00264	CcSEcCtD
Doxorubicin—YWHAG—central nervous system—amyotrophic lateral sclerosis	0.000826	0.00646	CbGeAlD
Doxorubicin—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00082	0.00263	CcSEcCtD
Doxorubicin—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00081	0.00259	CcSEcCtD
Doxorubicin—YWHAG—cerebellum—amyotrophic lateral sclerosis	0.000807	0.00631	CbGeAlD
Doxorubicin—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.0008	0.00256	CcSEcCtD
Doxorubicin—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.000788	0.00252	CcSEcCtD
Doxorubicin—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.000788	0.00252	CcSEcCtD
Doxorubicin—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.000778	0.00249	CcSEcCtD
Doxorubicin—RALBP1—nervous system—amyotrophic lateral sclerosis	0.000774	0.00606	CbGeAlD
Doxorubicin—POR—spinal cord—amyotrophic lateral sclerosis	0.000774	0.00605	CbGeAlD
Doxorubicin—NQO1—medulla oblongata—amyotrophic lateral sclerosis	0.000771	0.00603	CbGeAlD
Doxorubicin—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.000769	0.00246	CcSEcCtD
Doxorubicin—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.000766	0.00245	CcSEcCtD
Doxorubicin—NOS1—brain—amyotrophic lateral sclerosis	0.000766	0.00599	CbGeAlD
Doxorubicin—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.000762	0.00244	CcSEcCtD
Doxorubicin—NOS3—nervous system—amyotrophic lateral sclerosis	0.000762	0.00596	CbGeAlD
Doxorubicin—NDUFS2—brain—amyotrophic lateral sclerosis	0.000761	0.00595	CbGeAlD
Doxorubicin—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.000755	0.00242	CcSEcCtD
Doxorubicin—NDUFS3—brain—amyotrophic lateral sclerosis	0.000752	0.00588	CbGeAlD
Doxorubicin—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.000751	0.0024	CcSEcCtD
Doxorubicin—Infestation—Riluzole—amyotrophic lateral sclerosis	0.000751	0.0024	CcSEcCtD
Doxorubicin—RALBP1—central nervous system—amyotrophic lateral sclerosis	0.000746	0.00583	CbGeAlD
Doxorubicin—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.000736	0.00236	CcSEcCtD
Doxorubicin—NOS3—central nervous system—amyotrophic lateral sclerosis	0.000734	0.00574	CbGeAlD
Doxorubicin—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.000732	0.00234	CcSEcCtD
Doxorubicin—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.000732	0.00234	CcSEcCtD
Doxorubicin—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00073	0.00234	CcSEcCtD
Doxorubicin—RALBP1—cerebellum—amyotrophic lateral sclerosis	0.000729	0.0057	CbGeAlD
Doxorubicin—CBR1—nervous system—amyotrophic lateral sclerosis	0.000723	0.00565	CbGeAlD
Doxorubicin—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00072	0.00231	CcSEcCtD
Doxorubicin—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.000716	0.00229	CcSEcCtD
Doxorubicin—DHCR7—brain—amyotrophic lateral sclerosis	0.000714	0.00559	CbGeAlD
Doxorubicin—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00071	0.00227	CcSEcCtD
Doxorubicin—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.000708	0.00227	CcSEcCtD
Doxorubicin—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.000705	0.00226	CcSEcCtD
Doxorubicin—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.000701	0.00224	CcSEcCtD
Doxorubicin—CBR1—central nervous system—amyotrophic lateral sclerosis	0.000696	0.00544	CbGeAlD
Doxorubicin—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.000692	0.00541	CbGeAlD
Doxorubicin—ABCC10—medulla oblongata—amyotrophic lateral sclerosis	0.000689	0.00539	CbGeAlD
Doxorubicin—NQO1—spinal cord—amyotrophic lateral sclerosis	0.000687	0.00538	CbGeAlD
Doxorubicin—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.000686	0.0022	CcSEcCtD
Doxorubicin—CBR1—cerebellum—amyotrophic lateral sclerosis	0.00068	0.00532	CbGeAlD
Doxorubicin—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.000678	0.00217	CcSEcCtD
Doxorubicin—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.000676	0.00216	CcSEcCtD
Doxorubicin—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.000674	0.00216	CcSEcCtD
Doxorubicin—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.000674	0.00216	CcSEcCtD
Doxorubicin—AKR1C3—cerebellum—amyotrophic lateral sclerosis	0.000672	0.00526	CbGeAlD
Doxorubicin—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.000671	0.00215	CcSEcCtD
Doxorubicin—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.000669	0.00214	CcSEcCtD
Doxorubicin—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.000666	0.00213	CcSEcCtD
Doxorubicin—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.000664	0.00213	CcSEcCtD
Doxorubicin—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.000662	0.00212	CcSEcCtD
Doxorubicin—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.000661	0.00212	CcSEcCtD
Doxorubicin—YWHAG—brain—amyotrophic lateral sclerosis	0.000656	0.00513	CbGeAlD
Doxorubicin—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.000637	0.00204	CcSEcCtD
Doxorubicin—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00063	0.00202	CcSEcCtD
Doxorubicin—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.000626	0.002	CcSEcCtD
Doxorubicin—ABCC10—spinal cord—amyotrophic lateral sclerosis	0.000614	0.0048	CbGeAlD
Doxorubicin—POR—cerebellum—amyotrophic lateral sclerosis	0.000614	0.0048	CbGeAlD
Doxorubicin—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.000612	0.00196	CcSEcCtD
Doxorubicin—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.000609	0.00195	CcSEcCtD
Doxorubicin—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000608	0.00195	CcSEcCtD
Doxorubicin—Chills—Riluzole—amyotrophic lateral sclerosis	0.000605	0.00194	CcSEcCtD
Doxorubicin—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.000602	0.00193	CcSEcCtD
Doxorubicin—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.000596	0.00191	CcSEcCtD
Doxorubicin—RALBP1—brain—amyotrophic lateral sclerosis	0.000592	0.00463	CbGeAlD
Doxorubicin—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.000591	0.00189	CcSEcCtD
Doxorubicin—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.000587	0.00188	CcSEcCtD
Doxorubicin—NOS3—brain—amyotrophic lateral sclerosis	0.000582	0.00455	CbGeAlD
Doxorubicin—NQO1—nervous system—amyotrophic lateral sclerosis	0.000579	0.00453	CbGeAlD
Doxorubicin—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.000578	0.00185	CcSEcCtD
Doxorubicin—Tension—Riluzole—amyotrophic lateral sclerosis	0.000576	0.00184	CcSEcCtD
Doxorubicin—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.000575	0.00184	CcSEcCtD
Doxorubicin—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00057	0.00183	CcSEcCtD
Doxorubicin—Back pain—Riluzole—amyotrophic lateral sclerosis	0.000568	0.00182	CcSEcCtD
Doxorubicin—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.000564	0.00181	CcSEcCtD
Doxorubicin—NQO1—central nervous system—amyotrophic lateral sclerosis	0.000558	0.00436	CbGeAlD
Doxorubicin—CBR1—brain—amyotrophic lateral sclerosis	0.000553	0.00432	CbGeAlD
Doxorubicin—AKR1C3—brain—amyotrophic lateral sclerosis	0.000546	0.00427	CbGeAlD
Doxorubicin—NQO1—cerebellum—amyotrophic lateral sclerosis	0.000545	0.00426	CbGeAlD
Doxorubicin—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.000545	0.00174	CcSEcCtD
Doxorubicin—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000542	0.00174	CcSEcCtD
Doxorubicin—Agitation—Riluzole—amyotrophic lateral sclerosis	0.000539	0.00173	CcSEcCtD
Doxorubicin—Malaise—Riluzole—amyotrophic lateral sclerosis	0.000529	0.00169	CcSEcCtD
Doxorubicin—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.000527	0.00169	CcSEcCtD
Doxorubicin—Syncope—Riluzole—amyotrophic lateral sclerosis	0.000526	0.00169	CcSEcCtD
Doxorubicin—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.000525	0.00168	CcSEcCtD
Doxorubicin—ABCC3—nervous system—amyotrophic lateral sclerosis	0.00052	0.00407	CbGeAlD
Doxorubicin—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.000519	0.00166	CcSEcCtD
Doxorubicin—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000516	0.00165	CcSEcCtD
Doxorubicin—Cough—Riluzole—amyotrophic lateral sclerosis	0.000512	0.00164	CcSEcCtD
Doxorubicin—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.000508	0.00163	CcSEcCtD
Doxorubicin—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.000507	0.00162	CcSEcCtD
Doxorubicin—ABCC3—central nervous system—amyotrophic lateral sclerosis	0.000501	0.00391	CbGeAlD
Doxorubicin—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.0005	0.0016	CcSEcCtD
Doxorubicin—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.0005	0.0016	CcSEcCtD
Doxorubicin—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.0005	0.0016	CcSEcCtD
Doxorubicin—POR—brain—amyotrophic lateral sclerosis	0.000498	0.0039	CbGeAlD
Doxorubicin—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.000498	0.00159	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.000496	0.00159	CcSEcCtD
Doxorubicin—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000494	0.00158	CcSEcCtD
Doxorubicin—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.000489	0.00156	CcSEcCtD
Doxorubicin—ABCC10—cerebellum—amyotrophic lateral sclerosis	0.000487	0.00381	CbGeAlD
Doxorubicin—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.000483	0.00155	CcSEcCtD
Doxorubicin—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000479	0.00153	CcSEcCtD
Doxorubicin—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.000479	0.00153	CcSEcCtD
Doxorubicin—Infection—Riluzole—amyotrophic lateral sclerosis	0.000476	0.00152	CcSEcCtD
Doxorubicin—Shock—Riluzole—amyotrophic lateral sclerosis	0.000471	0.00151	CcSEcCtD
Doxorubicin—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00047	0.0015	CcSEcCtD
Doxorubicin—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000469	0.0015	CcSEcCtD
Doxorubicin—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000467	0.0015	CcSEcCtD
Doxorubicin—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000465	0.00149	CcSEcCtD
Doxorubicin—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000463	0.00148	CcSEcCtD
Doxorubicin—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.000457	0.00146	CcSEcCtD
Doxorubicin—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000448	0.00143	CcSEcCtD
Doxorubicin—NQO1—brain—amyotrophic lateral sclerosis	0.000443	0.00346	CbGeAlD
Doxorubicin—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000436	0.0014	CcSEcCtD
Doxorubicin—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000433	0.00139	CcSEcCtD
Doxorubicin—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00043	0.00138	CcSEcCtD
Doxorubicin—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000427	0.00137	CcSEcCtD
Doxorubicin—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000426	0.00136	CcSEcCtD
Doxorubicin—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000422	0.00135	CcSEcCtD
Doxorubicin—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000416	0.00133	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000413	0.00132	CcSEcCtD
Doxorubicin—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000413	0.00132	CcSEcCtD
Doxorubicin—Pain—Riluzole—amyotrophic lateral sclerosis	0.00041	0.00131	CcSEcCtD
Doxorubicin—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00041	0.00131	CcSEcCtD
Doxorubicin—CYP1B1—nervous system—amyotrophic lateral sclerosis	0.000407	0.00318	CbGeAlD
Doxorubicin—ABCG2—medulla oblongata—amyotrophic lateral sclerosis	0.000403	0.00315	CbGeAlD
Doxorubicin—ABCC3—brain—amyotrophic lateral sclerosis	0.000397	0.00311	CbGeAlD
Doxorubicin—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.000396	0.0031	CbGeAlD
Doxorubicin—ABCC10—brain—amyotrophic lateral sclerosis	0.000395	0.00309	CbGeAlD
Doxorubicin—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000395	0.00126	CcSEcCtD
Doxorubicin—CYP1B1—central nervous system—amyotrophic lateral sclerosis	0.000392	0.00306	CbGeAlD
Doxorubicin—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000392	0.00125	CcSEcCtD
Doxorubicin—CYP1B1—cerebellum—amyotrophic lateral sclerosis	0.000383	0.00299	CbGeAlD
Doxorubicin—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00038	0.00122	CcSEcCtD
Doxorubicin—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000379	0.00121	CcSEcCtD
Doxorubicin—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000379	0.00121	CcSEcCtD
Doxorubicin—ABCG2—spinal cord—amyotrophic lateral sclerosis	0.00036	0.00281	CbGeAlD
Doxorubicin—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000353	0.00113	CcSEcCtD
Doxorubicin—ABCC1—cerebellum—amyotrophic lateral sclerosis	0.000344	0.00269	CbGeAlD
Doxorubicin—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000344	0.0011	CcSEcCtD
Doxorubicin—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000339	0.00109	CcSEcCtD
Doxorubicin—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000328	0.00105	CcSEcCtD
Doxorubicin—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000317	0.00101	CcSEcCtD
Doxorubicin—ABCB1—embryo—amyotrophic lateral sclerosis	0.000311	0.00243	CbGeAlD
Doxorubicin—CYP1B1—brain—amyotrophic lateral sclerosis	0.000311	0.00243	CbGeAlD
Doxorubicin—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000305	0.000975	CcSEcCtD
Doxorubicin—Rash—Riluzole—amyotrophic lateral sclerosis	0.000302	0.000967	CcSEcCtD
Doxorubicin—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000302	0.000966	CcSEcCtD
Doxorubicin—Headache—Riluzole—amyotrophic lateral sclerosis	0.0003	0.000961	CcSEcCtD
Doxorubicin—ABCG2—cerebellum—amyotrophic lateral sclerosis	0.000285	0.00223	CbGeAlD
Doxorubicin—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000284	0.000911	CcSEcCtD
Doxorubicin—ABCC1—brain—amyotrophic lateral sclerosis	0.00028	0.00219	CbGeAlD
Doxorubicin—CYP2B6—nervous system—amyotrophic lateral sclerosis	0.000279	0.00219	CbGeAlD
Doxorubicin—CYP2B6—central nervous system—amyotrophic lateral sclerosis	0.000269	0.0021	CbGeAlD
Doxorubicin—ABCG2—brain—amyotrophic lateral sclerosis	0.000232	0.00181	CbGeAlD
Doxorubicin—CYP2B6—brain—amyotrophic lateral sclerosis	0.000214	0.00167	CbGeAlD
Doxorubicin—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000211	0.00165	CbGeAlD
Doxorubicin—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000208	0.00162	CbGeAlD
Doxorubicin—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000203	0.00159	CbGeAlD
Doxorubicin—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.0002	0.00156	CbGeAlD
Doxorubicin—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000199	0.00155	CbGeAlD
Doxorubicin—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000195	0.00153	CbGeAlD
Doxorubicin—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000177	0.00139	CbGeAlD
Doxorubicin—CYP2D6—brain—amyotrophic lateral sclerosis	0.000159	0.00124	CbGeAlD
Doxorubicin—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000149	0.00117	CbGeAlD
Doxorubicin—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000144	0.00112	CbGeAlD
Doxorubicin—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000141	0.0011	CbGeAlD
Doxorubicin—ABCB1—brain—amyotrophic lateral sclerosis	0.000114	0.000893	CbGeAlD
Doxorubicin—AKR1C3—Metabolism—CHAT—amyotrophic lateral sclerosis	5.21e-05	0.000274	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—VAPA—amyotrophic lateral sclerosis	5.2e-05	0.000274	CbGpPWpGaD
Doxorubicin—ABCC2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	5.16e-05	0.000272	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—FIG4—amyotrophic lateral sclerosis	5.16e-05	0.000272	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—VCP—amyotrophic lateral sclerosis	5.12e-05	0.00027	CbGpPWpGaD
Doxorubicin—ABCC1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	5.1e-05	0.000269	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	5.06e-05	0.000267	CbGpPWpGaD
Doxorubicin—NDUFS7—Metabolism—APOE—amyotrophic lateral sclerosis	5.04e-05	0.000265	CbGpPWpGaD
Doxorubicin—NDUFS3—Metabolism—APOE—amyotrophic lateral sclerosis	5.04e-05	0.000265	CbGpPWpGaD
Doxorubicin—ABCG2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	5.04e-05	0.000265	CbGpPWpGaD
Doxorubicin—ABCG2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	5.04e-05	0.000265	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—FIG4—amyotrophic lateral sclerosis	4.99e-05	0.000263	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	4.97e-05	0.000262	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.97e-05	0.000262	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	4.96e-05	0.000261	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.9e-05	0.000258	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	4.85e-05	0.000256	CbGpPWpGaD
Doxorubicin—NOS2—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	4.85e-05	0.000255	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—CHAT—amyotrophic lateral sclerosis	4.84e-05	0.000255	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.83e-05	0.000254	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	4.82e-05	0.000254	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	4.75e-05	0.00025	CbGpPWpGaD
Doxorubicin—NDUFS2—Metabolism—APOE—amyotrophic lateral sclerosis	4.74e-05	0.000249	CbGpPWpGaD
Doxorubicin—NOS1—Disease—ERBB4—amyotrophic lateral sclerosis	4.71e-05	0.000248	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PLB1—amyotrophic lateral sclerosis	4.71e-05	0.000248	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—IGF1—amyotrophic lateral sclerosis	4.69e-05	0.000247	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CHMP2B—amyotrophic lateral sclerosis	4.67e-05	0.000246	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—DAO—amyotrophic lateral sclerosis	4.67e-05	0.000246	CbGpPWpGaD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	4.57e-05	0.000241	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.57e-05	0.00024	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	4.56e-05	0.00024	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—FIG4—amyotrophic lateral sclerosis	4.54e-05	0.000239	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PLB1—amyotrophic lateral sclerosis	4.51e-05	0.000238	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—DAO—amyotrophic lateral sclerosis	4.51e-05	0.000238	CbGpPWpGaD
Doxorubicin—ABCG2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	4.49e-05	0.000236	CbGpPWpGaD
Doxorubicin—NOS3—Disease—CST3—amyotrophic lateral sclerosis	4.43e-05	0.000233	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	4.4e-05	0.000232	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—CHAT—amyotrophic lateral sclerosis	4.4e-05	0.000232	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	4.35e-05	0.000229	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—GSR—amyotrophic lateral sclerosis	4.35e-05	0.000229	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—VCP—amyotrophic lateral sclerosis	4.33e-05	0.000228	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PLB1—amyotrophic lateral sclerosis	4.22e-05	0.000222	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	4.21e-05	0.000222	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	4.19e-05	0.000221	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—GSR—amyotrophic lateral sclerosis	4.17e-05	0.000219	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—TPK1—amyotrophic lateral sclerosis	4.16e-05	0.000219	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—VAPB—amyotrophic lateral sclerosis	4.16e-05	0.000219	CbGpPWpGaD
Doxorubicin—NOS2—Disease—CASP9—amyotrophic lateral sclerosis	4.15e-05	0.000219	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	4.13e-05	0.000217	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—DAO—amyotrophic lateral sclerosis	4.11e-05	0.000216	CbGpPWpGaD
Doxorubicin—NOS1—Hemostasis—VEGFA—amyotrophic lateral sclerosis	4.06e-05	0.000214	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—APOE—amyotrophic lateral sclerosis	4.03e-05	0.000212	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.96e-05	0.000208	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	3.88e-05	0.000204	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—CASP9—amyotrophic lateral sclerosis	3.82e-05	0.000201	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—VAPA—amyotrophic lateral sclerosis	3.81e-05	0.000201	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.79e-05	0.0002	CbGpPWpGaD
Doxorubicin—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	3.78e-05	0.000199	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—VCP—amyotrophic lateral sclerosis	3.77e-05	0.000198	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—APOE—amyotrophic lateral sclerosis	3.76e-05	0.000198	CbGpPWpGaD
Doxorubicin—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	3.73e-05	0.000196	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	3.72e-05	0.000196	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	3.68e-05	0.000194	CbGpPWpGaD
Doxorubicin—NOS1—Disease—APOE—amyotrophic lateral sclerosis	3.65e-05	0.000192	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—IGF1—amyotrophic lateral sclerosis	3.64e-05	0.000192	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	3.59e-05	0.000189	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—CHAT—amyotrophic lateral sclerosis	3.57e-05	0.000188	CbGpPWpGaD
Doxorubicin—NOS2—Disease—ERBB4—amyotrophic lateral sclerosis	3.55e-05	0.000187	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	3.55e-05	0.000187	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.54e-05	0.000186	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PLB1—amyotrophic lateral sclerosis	3.54e-05	0.000186	CbGpPWpGaD
Doxorubicin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	3.52e-05	0.000185	CbGpPWpGaD
Doxorubicin—NDUFS7—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.45e-05	0.000182	CbGpPWpGaD
Doxorubicin—NDUFS3—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.45e-05	0.000182	CbGpPWpGaD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	3.45e-05	0.000182	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—C3—amyotrophic lateral sclerosis	3.43e-05	0.000181	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—CHAT—amyotrophic lateral sclerosis	3.42e-05	0.00018	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PLB1—amyotrophic lateral sclerosis	3.42e-05	0.00018	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	3.39e-05	0.000178	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—FIG4—amyotrophic lateral sclerosis	3.33e-05	0.000175	CbGpPWpGaD
Doxorubicin—TOP2A—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	3.31e-05	0.000174	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—ERBB4—amyotrophic lateral sclerosis	3.27e-05	0.000172	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—GSR—amyotrophic lateral sclerosis	3.26e-05	0.000172	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	3.26e-05	0.000171	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.26e-05	0.000171	CbGpPWpGaD
Doxorubicin—NDUFS2—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.25e-05	0.000171	CbGpPWpGaD
Doxorubicin—NOS3—Disease—CASP9—amyotrophic lateral sclerosis	3.22e-05	0.00017	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	3.2e-05	0.000169	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	3.19e-05	0.000168	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—GSR—amyotrophic lateral sclerosis	3.16e-05	0.000166	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	3.12e-05	0.000164	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PLB1—amyotrophic lateral sclerosis	3.11e-05	0.000164	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	3.07e-05	0.000162	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	3.07e-05	0.000162	CbGpPWpGaD
Doxorubicin—NOS1—Hemostasis—TP53—amyotrophic lateral sclerosis	3.07e-05	0.000162	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—VEGFA—amyotrophic lateral sclerosis	3.07e-05	0.000161	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	3.05e-05	0.000161	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—DAO—amyotrophic lateral sclerosis	3.01e-05	0.000159	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.99e-05	0.000158	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.97e-05	0.000157	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.9e-05	0.000153	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	2.89e-05	0.000152	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	2.89e-05	0.000152	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.88e-05	0.000151	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—GSR—amyotrophic lateral sclerosis	2.87e-05	0.000151	CbGpPWpGaD
Doxorubicin—AURKA—Cell Cycle—TP53—amyotrophic lateral sclerosis	2.82e-05	0.000148	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	2.81e-05	0.000148	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.81e-05	0.000148	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.8e-05	0.000147	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.76e-05	0.000145	CbGpPWpGaD
Doxorubicin—NOS3—Disease—ERBB4—amyotrophic lateral sclerosis	2.76e-05	0.000145	CbGpPWpGaD
Doxorubicin—NOS2—Disease—APOE—amyotrophic lateral sclerosis	2.75e-05	0.000145	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	2.72e-05	0.000143	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	2.72e-05	0.000143	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CST3—amyotrophic lateral sclerosis	2.7e-05	0.000142	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—CHAT—amyotrophic lateral sclerosis	2.68e-05	0.000141	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.67e-05	0.000141	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.67e-05	0.00014	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	2.65e-05	0.000139	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.64e-05	0.000139	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.61e-05	0.000138	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.6e-05	0.000137	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—CHAT—amyotrophic lateral sclerosis	2.59e-05	0.000137	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.57e-05	0.000136	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.57e-05	0.000135	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.53e-05	0.000133	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—APOE—amyotrophic lateral sclerosis	2.53e-05	0.000133	CbGpPWpGaD
Doxorubicin—NOS1—Disease—PTGS2—amyotrophic lateral sclerosis	2.5e-05	0.000132	CbGpPWpGaD
Doxorubicin—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	2.47e-05	0.00013	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.46e-05	0.00013	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	2.46e-05	0.000129	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.45e-05	0.000129	CbGpPWpGaD
Doxorubicin—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	2.44e-05	0.000128	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	2.43e-05	0.000128	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.39e-05	0.000126	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—VEGFA—amyotrophic lateral sclerosis	2.38e-05	0.000125	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.37e-05	0.000125	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.37e-05	0.000125	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.36e-05	0.000125	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—CHAT—amyotrophic lateral sclerosis	2.36e-05	0.000124	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—TP53—amyotrophic lateral sclerosis	2.32e-05	0.000122	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	2.31e-05	0.000122	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	2.3e-05	0.000121	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.29e-05	0.00012	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PLB1—amyotrophic lateral sclerosis	2.28e-05	0.00012	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.26e-05	0.000119	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	2.23e-05	0.000117	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	2.22e-05	0.000117	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—APOE—amyotrophic lateral sclerosis	2.19e-05	0.000115	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.17e-05	0.000114	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.15e-05	0.000113	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	2.14e-05	0.000113	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle—TP53—amyotrophic lateral sclerosis	2.14e-05	0.000112	CbGpPWpGaD
Doxorubicin—NOS3—Disease—APOE—amyotrophic lateral sclerosis	2.13e-05	0.000112	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—APOE—amyotrophic lateral sclerosis	2.12e-05	0.000111	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—GSR—amyotrophic lateral sclerosis	2.11e-05	0.000111	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	2.09e-05	0.00011	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.03e-05	0.000107	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—APOE—amyotrophic lateral sclerosis	1.97e-05	0.000104	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CASP9—amyotrophic lateral sclerosis	1.96e-05	0.000103	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.93e-05	0.000102	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.92e-05	0.000101	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.92e-05	0.000101	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	1.91e-05	0.000101	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.9e-05	0.0001	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	1.89e-05	9.96e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	1.89e-05	9.96e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—PTGS2—amyotrophic lateral sclerosis	1.88e-05	9.92e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.84e-05	9.68e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.82e-05	9.57e-05	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—TP53—amyotrophic lateral sclerosis	1.8e-05	9.47e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—APOE—amyotrophic lateral sclerosis	1.79e-05	9.41e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	1.77e-05	9.33e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.77e-05	9.32e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.76e-05	9.28e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—PTGS2—amyotrophic lateral sclerosis	1.73e-05	9.12e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	1.73e-05	9.11e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CHAT—amyotrophic lateral sclerosis	1.73e-05	9.11e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.72e-05	9.07e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.69e-05	8.9e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	1.68e-05	8.86e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—ERBB4—amyotrophic lateral sclerosis	1.68e-05	8.85e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.68e-05	8.83e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.62e-05	8.54e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.61e-05	8.47e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.61e-05	8.46e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	1.59e-05	8.35e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	1.55e-05	8.18e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	1.51e-05	7.97e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	1.5e-05	7.92e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.5e-05	7.91e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.49e-05	7.87e-05	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—TP53—amyotrophic lateral sclerosis	1.49e-05	7.87e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	1.46e-05	7.71e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—PTGS2—amyotrophic lateral sclerosis	1.46e-05	7.7e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.46e-05	7.7e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—APOE—amyotrophic lateral sclerosis	1.45e-05	7.64e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.45e-05	7.63e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.44e-05	7.59e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.39e-05	7.34e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—APOE—amyotrophic lateral sclerosis	1.39e-05	7.32e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	1.37e-05	7.2e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.35e-05	7.1e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.32e-05	6.97e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.3e-05	6.86e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—APOE—amyotrophic lateral sclerosis	1.3e-05	6.85e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.28e-05	6.74e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.28e-05	6.72e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.27e-05	6.68e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.24e-05	6.5e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.23e-05	6.45e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	1.2e-05	6.33e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.17e-05	6.14e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	1.14e-05	5.98e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.13e-05	5.93e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—APOE—amyotrophic lateral sclerosis	1.09e-05	5.74e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.06e-05	5.6e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—APOE—amyotrophic lateral sclerosis	1.05e-05	5.55e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	1.04e-05	5.46e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PTGS2—amyotrophic lateral sclerosis	9.94e-06	5.23e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—APOE—amyotrophic lateral sclerosis	9.59e-06	5.05e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	9.57e-06	5.04e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	9.55e-06	5.03e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PTGS2—amyotrophic lateral sclerosis	9.53e-06	5.02e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.51e-06	5.01e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.29e-06	4.89e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.99e-06	4.73e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PTGS2—amyotrophic lateral sclerosis	8.91e-06	4.69e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.54e-06	4.5e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.07e-06	4.25e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	7.86e-06	4.14e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.46e-06	3.93e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.22e-06	3.8e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	7.22e-06	3.8e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—APOE—amyotrophic lateral sclerosis	7.03e-06	3.7e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.86e-06	3.61e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.57e-06	3.46e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.46e-06	3.4e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.3e-06	3.32e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.1e-06	3.21e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.94e-06	3.13e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	5.18e-06	2.73e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	4.88e-06	2.57e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.82e-06	2.54e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.22e-06	2.22e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.88e-06	2.04e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.55e-06	1.87e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.35e-06	1.76e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	3.19e-06	1.68e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.19e-06	1.15e-05	CbGpPWpGaD
